The other day I went online and decided, for the first time in a while, to check the price of the {$XBI}. I blinked, rubbed my eyes, and blinked again. 100??? What year is it? Quietly, gradually and after months of bummer vibes, people are asking: Is biotech back?
The S&P biotech index is up to levels it hasn’t seen since 2022, pharma’s deals with President Donald Trump appear to have taken off some pricing pressure, M&A is cooking, interest rates are starting to come down, and there’s even a smattering of IPOs. It’s almost enough to make you trust again...
Today on Post-Hoc Live, I spoke with one of our favorite writers on the market, Stifel Investment Banking’s Tim Opler, whose weekly deep dives are a must-read. And our founding editor, John Carroll, joined: John has just published a two-part look at dealmaking over the last year, and has a strong view on what’s happening out there.
Come and check the vibes with us on YouTube, or listen on Spotify or Apple Podcasts. Thanks for watching!
— Drew Armstrong, Executive Editor
↧